Global review of Alzheimer’s drug trials published
A review of clinical trials for Alzheimer’s disease drugs has been published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
Entitled ‘Alzheimer’s disease drug development pipeline: 2026’, this is the latest annual review from Dr Jeffrey Cummings, from the University of Nevada, who has published reviews for the past decade that look at clinical trials for Alzheimer’s disease.
Dr Cummings says:
“Anti‑amyloid medicines such as lecanemab and donanemab have been a crucial breakthrough. They’ve shown that directly targeting the disease’s process can slow decline. But they are only the beginning of what people with Alzheimer’s will ultimately need.”
Read the 2026 review here: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70251